GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
GeneDx (Nasdaq: WGS) has appointed Heidi Chen as Chief Legal Officer and Corporate Secretary, effective November 25, 2024. Chen, who will report to CEO Katherine Stueland, brings over 30 years of experience and will lead legal, compliance, and policy functions. She joins from Zoetis, where she served as General Counsel for nearly 12 years following its spinoff from Pfizer in 2013. During her tenure at Zoetis, Chen built the legal department and managed global security, enterprise risk management, M&A, litigation, and corporate governance. She previously held leadership positions at Pfizer and started her career at Hughes & Hubbard and Clifford Chance.
GeneDx (Nasdaq: WGS) ha nominato Heidi Chen come Direttore Legale e Segretario Aziendale, con effetto dal 25 novembre 2024. Chen, che risponderà al CEO Katherine Stueland, porta con sé oltre 30 anni di esperienza e guiderà le funzioni legali, di conformità e politiche. Arriva da Zoetis, dove ha ricoperto il ruolo di Consigliere Generale per quasi 12 anni, dopo la scissione da Pfizer nel 2013. Durante il suo mandato in Zoetis, Chen ha costruito il dipartimento legale e gestito la sicurezza globale, la gestione del rischio aziendale, le fusioni e acquisizioni, le contenziosi e la governance aziendale. In precedenza ha ricoperto posizioni dirigenziali in Pfizer e ha iniziato la sua carriera in Hughes & Hubbard e Clifford Chance.
GeneDx (Nasdaq: WGS) ha nombrado a Heidi Chen como Directora Legal y Secretaria Corporativa, con efecto a partir del 25 de noviembre de 2024. Chen, quien reportará a la CEO Katherine Stueland, aporta más de 30 años de experiencia y liderará las funciones legales, de cumplimiento y políticas. Se une a Zoetis, donde se desempeñó como Consejera General durante casi 12 años tras su escisión de Pfizer en 2013. Durante su tiempo en Zoetis, Chen construyó el departamento legal y gestionó la seguridad global, la gestión de riesgos empresariales, fusiones y adquisiciones, litigios y la gobernanza corporativa. Anteriormente ocupó cargos de liderazgo en Pfizer y comenzó su carrera en Hughes & Hubbard y Clifford Chance.
GeneDx (Nasdaq: WGS)는 Heidi Chen을 법률담당 최고 책임자 및 기업 비서로 임명했습니다. 이 임명은 2024년 11월 25일부터 효력이 발생합니다. Chen은 CEO인 Katherine Stueland에게 보고하며 30년 이상의 경험을 가지고 있으며 법률, 준수 및 정책 기능을 이끌게 됩니다. Chen은 2013년 Pfizer로부터 분사된 후 거의 12년 동안 Zoetis의 총괄 변호사로 재직하였습니다. Zoetis에서의 기간 동안 Chen은 법무부를 구축하고 글로벌 보안, 기업 위험 관리, 인수 합병, 소송 및 기업 거버넌스를 관리했습니다. 그녀는 이전에 Pfizer에서 리더십 직책을 맡았으며 Hughes & Hubbard와 Clifford Chance에서 경력을 시작했습니다.
GeneDx (Nasdaq: WGS) a nommé Heidi Chen en tant que Directrice Juridique et Secrétaire Général, à compter du 25 novembre 2024. Chen, qui reportera à la PDG Katherine Stueland, possède plus de 30 ans d'expérience et dirigera les fonctions juridiques, de conformité et de politique. Elle rejoint Zoetis, où elle a été avocate générale pendant près de 12 ans après sa séparation de Pfizer en 2013. Pendant son mandat chez Zoetis, Chen a construit le département juridique et géré la sécurité mondiale, la gestion des risques d'entreprise, les fusions et acquisitions, les litiges et la gouvernance d'entreprise. Auparavant, elle a occupé des postes de direction chez Pfizer et a commencé sa carrière chez Hughes & Hubbard et Clifford Chance.
GeneDx (Nasdaq: WGS) hat Heidi Chen zur Chief Legal Officer und Corporate Secretary ernannt, mit Wirkung zum 25. November 2024. Chen, die an CEO Katherine Stueland berichtet, bringt über 30 Jahre Erfahrung mit und wird die rechtlichen, compliance- und politikbezogenen Funktionen leiten. Sie kommt von Zoetis, wo sie fast 12 Jahre lang als General Counsel tätig war, nachdem sich das Unternehmen 2013 von Pfizer abgespalten hatte. Während ihrer Zeit bei Zoetis baute Chen die Rechtsabteilung auf und kümmerte sich um globale Sicherheit, Unternehmensrisikomanagement, Fusionen und Übernahmen, Rechtsstreitigkeiten und Corporate Governance. Zuvor hatte sie Führungspositionen bei Pfizer inne und begann ihre Karriere bei Hughes & Hubbard und Clifford Chance.
- Appointment of experienced legal executive with 30+ years of expertise
- Strong track record in managing legal operations for major healthcare companies
- Experience in M&A, litigation, and corporate governance from Zoetis and Pfizer
- None.
Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions
With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.
“With a massive transformation behind us and a clear runway for growth ahead, Heidi brings the expertise and leadership needed to guide GeneDx into this next chapter, particularly given the changing landscape in healthcare,” said Stueland. “Heidi is a celebrated and well-respected business leader and general counsel who brings extensive industry expertise to GeneDx. I’m happy to welcome Heidi to our executive leadership team to shape our business and legal strategy to advance critical initiatives to drive innovation as we enter this next phase of growth for our business.”
Heidi joins GeneDx from Zoetis, where she served as General Counsel for nearly 12 years, a role she assumed following the company’s spinoff from Pfizer in 2013. During her tenure at Zoetis, she was instrumental in building the company’s legal department and establishing essential processes to support the company’s rapid growth. Heidi also oversaw global security, enterprise risk management, M&A, litigation and all corporate governance. In addition to her legal oversight, she also led operational strategy for a specialized human health diagnostics segment within the Zoetis business. Prior to the spinoff Heidi held a variety of leadership positions on Pfizer’s legal team and worked across compliance, litigation, licensing and risk management. She began her career with roles at Hughes & Hubbard and Clifford Chance. Heidi holds a J.D. from Cornell Law School and a B.S. from Yale University.
“I’m honored to have the opportunity to help accelerate GeneDx’s growth and continue transforming patient care,” said Chen. “I look forward to collaborating with the talented team at GeneDx to push boundaries, drive disruptive change, and pioneer innovations that deliver meaningful improvements in health outcomes.”
About GeneDx:
GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world’s largest, rare disease data sets. For more information, please visit www.genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241118085768/en/
Press@genedx.com
Investors@genedx.com
Source: GeneDx
FAQ
When will Heidi Chen start as Chief Legal Officer at GeneDx (WGS)?
What was Heidi Chen's previous role before joining GeneDx (WGS)?
What will be Heidi Chen's responsibilities at GeneDx (WGS)?
